Development of rapid on site cytologic evaluation using artificial intelligence (AI-ROSE) during EUS-FNA

Development of rapid on site cytologic evaluation using artificial intelligence (AI-ROSE) during EUS-FNA - AI-ROSE

Status

Recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000042212

Enrollment

200

Registered

2020-10-22

Start date

2020-09-08

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Pancreatic Cancer

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1) Patients with a solid pancreatic mass who underwent ROSE during EUS-FNA and have a preparatory structure capable of pathological cytology. 2) Cases with a definitive diagnosis of pancreatitis or pancreatic cancer

Exclusion criteria

Exclusion criteria: Cases without ROSE during EUS-FNA

Design outcomes

Primary

Measure	Time frame
Diagnostic ability in ROSE during EUS-FNA for pancreatic tumor using AI	—

Countries

Japan

Contacts

Public ContactREIKO ASHIDA

Wakayama Medical University Second Department of Internal Medicine

ninai@wakayama-med.acj.jp073-441-0627

Outcome results